These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Modification of Parkinsonism--chronic treatment with L-dopa. Cotzias GC; Papavasiliou PS; Gellene R N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641 [No Abstract] [Full Text] [Related]
4. Efficacy of and possible differences in tolerance to L-dopa tablets with different rates of release of the active substance. Völler GW; Muschard F Acta Neurol Scand; 1974; 50(3):391-3. PubMed ID: 4525037 [No Abstract] [Full Text] [Related]
5. L-dopa in Parkinsonism and the influence of previous thalamotomy. Hughes RC; Polgar JG; Weightman D; Walton JN Br Med J; 1971 Jan; 1(5739):7-13. PubMed ID: 4923653 [TBL] [Abstract][Full Text] [Related]
6. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias. Klawans HL; Weiner WJ J Neurol Neurosurg Psychiatry; 1974 Apr; 37(4):427-30. PubMed ID: 4838914 [TBL] [Abstract][Full Text] [Related]
7. Side effects of L-dopa treatment. Greenburg J Pa Med; 1971 Apr; 74(4):55-6. PubMed ID: 5147645 [No Abstract] [Full Text] [Related]
9. L-Dopa in the treatment of parkinsonism. Calne DB Clin Pharmacol Ther; 1970; 11(6):789-801. PubMed ID: 4921292 [No Abstract] [Full Text] [Related]
10. L-dopa in the treatment of parkinsonism. Haleem MA Gerontol Clin (Basel); 1972; 14(4):242-8. PubMed ID: 4634915 [No Abstract] [Full Text] [Related]
11. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)]. Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081 [No Abstract] [Full Text] [Related]
13. [Use of L-DOPA in the therapy of parkinsonism]. D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734 [No Abstract] [Full Text] [Related]
14. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease. Andrews CJ; Somerville B Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384 [No Abstract] [Full Text] [Related]
15. [10 years of L-DOPA therapy of Parkinson's syndrome]. Birkmayer W Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333 [No Abstract] [Full Text] [Related]
16. L-Dopa treatment in Parkinson's Disease. Rinne UK; Sonninen V; Siirtola T Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969 [No Abstract] [Full Text] [Related]
17. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders. Timberlake WH Neurology; 1970 Dec; 20(12):Suppl:31-5. PubMed ID: 4921586 [No Abstract] [Full Text] [Related]
18. Combined L-dopa and amantadine in Parkinsonism. Pollock M; Jorgensen PB Aust N Z J Med; 1972 Aug; 2(3):252-5. PubMed ID: 4564049 [No Abstract] [Full Text] [Related]
19. Use of drugs in the treatment of parkinsonism. Nutr Rev; 1970 Jan; 28(1):7-9. PubMed ID: 4906659 [No Abstract] [Full Text] [Related]
20. [Long-term treatment of Parkinsonism with L-dopa]. Presthus J; Holmsen R Tidsskr Nor Laegeforen; 1972 Nov; 92(33):2262-6. PubMed ID: 4630916 [No Abstract] [Full Text] [Related] [Next] [New Search]